Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Engrail Therapeutics

Request full access

Acquiring, developing and commercializing transformative medicines

San Diego, United StatesFounded 2019Biotech & Life Sciences

About Engrail Therapeutics

Engrail Therapeutics is a clinical-stage pharmaceutical company dedicated to developing therapies for neurological and psychiatric disorders. The company's pipeline includes ENX-102, a GABAA positive allosteric modulator for generalized anxiety disorder, and ENX-104, a D2/D3 antagonist for major depressive disorder with anhedonia. Engrail's business model focuses on advancing its drug candidates through clinical trials to obtain regulatory approval and subsequent commercialization. The company targets the large and growing market for mental health treatments, a sector with significant unmet needs.

Engrail has secured substantial funding from venture capital firms, including a recent oversubscribed $157 million Series B financing round. This capital is being used to advance its clinical programs and expand its pipeline. The company's strategy involves building strong partnerships to support its research and development efforts. By focusing on precision neuroscience, Engrail aims to develop targeted therapies that offer improved efficacy and safety profiles compared to existing treatments.

Source: Dealroom company data

At a glance

Status
Operational
Employees
34
Open positions
None listed
Dealroom signal
70.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Investment activity
1 company, latest Feb 2021
Capital deployed
—
Preferred round
ACQUISITION

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Mar 2024 $157M $628M Eight Roads Ventures · Pivotal Life Sciences · Forbion Capital Partners · Norwest Venture Partners ↗
SERIES AOther financing Aug 2021 $32M $128M Pivotal Life Sciences · Nan Fung Life Sciences Real Estate —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Engrail Therapeutics website traffic

Latest recorded traffic for Engrail Therapeutics is 1.7K monthly website visits, up 13.3% over the last three months. Engrail Therapeutics's team declined 5.6% over the past year.

Latest monthly visits1.7K 3-month web change+13.3% 1-year team growth-5.6%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Engrail Therapeutics in the San Diego ecosystem

Live from Dealroom

The Engrail Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A10 investors entered at this stage

Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
5 countries with
team presence
🇺🇸 United States84.6%
🇬🇧 United Kingdom3.9%
🇳🇱 Netherlands3.9%
🇪🇸 Spain3.9%
🇮🇳 India3.9%
5 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Engrail Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Engrail Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.